Hancock Whitney Corp Has $800,000 Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Hancock Whitney Corp trimmed its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,322 shares of the biopharmaceutical company’s stock after selling 606 shares during the period. Hancock Whitney Corp’s holdings in Catalyst Pharmaceuticals were worth $800,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Catalyst Pharmaceuticals by 4.9% in the fourth quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock worth $175,957,000 after purchasing an additional 390,116 shares during the period. Pacer Advisors Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 5.4% during the 4th quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after acquiring an additional 151,495 shares during the period. Renaissance Technologies LLC boosted its position in shares of Catalyst Pharmaceuticals by 7.1% during the 4th quarter. Renaissance Technologies LLC now owns 2,706,116 shares of the biopharmaceutical company’s stock valued at $56,477,000 after acquiring an additional 180,100 shares in the last quarter. Boston Partners increased its stake in Catalyst Pharmaceuticals by 1.3% in the fourth quarter. Boston Partners now owns 1,291,868 shares of the biopharmaceutical company’s stock valued at $27,325,000 after acquiring an additional 16,601 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in Catalyst Pharmaceuticals by 6.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company’s stock worth $26,023,000 after purchasing an additional 79,182 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Up 1.1 %

Shares of CPRX stock opened at $23.45 on Friday. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.47 and a 1 year high of $26.16. The firm’s 50 day moving average is $22.58 and its 200-day moving average is $22.18. The firm has a market capitalization of $2.86 billion, a price-to-earnings ratio of 19.87, a PEG ratio of 3.31 and a beta of 0.79.

Insiders Place Their Bets

In related news, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 10.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CPRX. Robert W. Baird upped their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Bank of America reiterated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Finally, Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $32.29.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.